Spots Global Cancer Trial Database for savolitinib
Every month we try and update this database with for savolitinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) | NCT05620628 | Stomach Cancer,... | Durvalumab Savolitinib | 19 Years - | Samsung Medical Center | |
| Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC | NCT05163249 | Carcinoma, Non-... | Osimertinib Savolitinib | 18 Years - | Guangdong Association of Clinical Trials | |
| A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) | NCT02127710 | Papillary Renal... | AZD6094 | 18 Years - 99 Years | AstraZeneca | |
| Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC | NCT05009836 | Non-small Cell ... | Savolitinib Placebo | 28 Years - | Hutchmed | |
| Savolitinib vs. Sunitinib in MET-driven PRCC. | NCT03091192 | Carcinoma Carcinoma, Rena... Kidney Neoplasm... Urologic Neopla... Kidney Diseases Neoplasms by Si... Enzyme Inhibito... Protein Kinase ... | Savolitinib Sunitinib | 18 Years - 130 Years | AstraZeneca | |
| Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC | NCT05374603 | Lung Cancer | Savolitinib Durvalumab | - | AstraZeneca | |
| A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body | NCT04187456 | Solid Tumors | Savolitinib Midazolam | 18 Years - 65 Years | AstraZeneca | |
| Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance | NCT03833440 | Non-small Cell ... | Durvalumab (MED... Monalizumab (IP... Oleclumab (MEDI... Ceralasertib (A... DOCETAXEL Savolitinib | 18 Years - | Assistance Publique Hopitaux De Marseille | |
| Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment | NCT05261399 | Carcinoma Non-Small-Cell ... | Savolitinib Osimertinib Pemetrexed Cisplatin Carboplatin | 18 Years - 130 Years | AstraZeneca | |
| Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | NCT03778229 | Carcinoma | osimertinib savolitinib placebo | 18 Years - | AstraZeneca | |
| Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients | NCT04923945 | Non-small Cell ... | Savolitinib | 18 Years - | Hutchmed | |
| Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC | NCT05374603 | Lung Cancer | Savolitinib Durvalumab | - | AstraZeneca | |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | NCT02117167 | Non-small Cell ... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Standard mainte... Pemetrexed Durvalumab savolitinib Olaparib | 18 Years - | UNICANCER | |
| A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer | NCT02897479 | Lung Sarcomatoi... | Savolitinib | 18 Years - | Hutchmed | |
| Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance | NCT03833440 | Non-small Cell ... | Durvalumab (MED... Monalizumab (IP... Oleclumab (MEDI... Ceralasertib (A... DOCETAXEL Savolitinib | 18 Years - | Assistance Publique Hopitaux De Marseille | |
| Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC | NCT05163249 | Carcinoma, Non-... | Osimertinib Savolitinib | 18 Years - | Guangdong Association of Clinical Trials | |
| Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors | NCT03598244 | Recurrent Diffu... Recurrent Malig... Recurrent Medul... Recurrent Prima... Refractory Diff... Refractory Mali... Refractory Medu... Refractory Prim... | Biospecimen Col... Magnetic Resona... Savolitinib X-Ray Imaging | 6 Years - 21 Years | National Cancer Institute (NCI) | |
| AZD9291 in Combination With Ascending Doses of Novel Therapeutics | NCT02143466 | Advanced Non Sm... | Part A - AZD929... Part A - AZD929... Part A - AZD929... Part A - AZD929... Part A - AZD929... Part B - AZD929... Part B - AZD929... Part B - AZD929... Part C - AZD609... Part C - AZD929... Part D - AZD929... | 18 Years - 130 Years | AstraZeneca | |
| Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC | NCT05009836 | Non-small Cell ... | Savolitinib Placebo | 28 Years - | Hutchmed | |
| A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine | NCT04179071 | Solid Tumours | Savolitinib Famotidine | 18 Years - 65 Years | AstraZeneca | |
| Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed | NCT02761057 | Locally Advance... Metastatic Papi... Stage III Renal... Stage IV Renal ... Type 1 Papillar... Type 2 Papillar... Unresectable Re... | Biospecimen Col... Bone Scan Cabozantinib S-... Computed Tomogr... Crizotinib Savolitinib Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | NCT02117167 | Non-small Cell ... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Standard mainte... Pemetrexed Durvalumab savolitinib Olaparib | 18 Years - | UNICANCER | |
| Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | NCT03778229 | Carcinoma | osimertinib savolitinib placebo | 18 Years - | AstraZeneca | |
| Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression | NCT05777278 | Non-small Cell ... | Savolitinib Docetaxel | 18 Years - | The First Affiliated Hospital of Guangzhou Medical University | |
| Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors | NCT03598244 | Recurrent Diffu... Recurrent Malig... Recurrent Medul... Recurrent Prima... Refractory Diff... Refractory Mali... Refractory Medu... Refractory Prim... | Biospecimen Col... Magnetic Resona... Savolitinib X-Ray Imaging | 6 Years - 21 Years | National Cancer Institute (NCI) | |
| Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance | NCT03833440 | Non-small Cell ... | Durvalumab (MED... Monalizumab (IP... Oleclumab (MEDI... Ceralasertib (A... DOCETAXEL Savolitinib | 18 Years - | Assistance Publique Hopitaux De Marseille | |
| A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC | NCT04606771 | Non-Small Cell ... | Osimertinib + S... Savolitinib + P... | 18 Years - | AstraZeneca | |
| Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment | NCT05261399 | Carcinoma Non-Small-Cell ... | Savolitinib Osimertinib Pemetrexed Cisplatin Carboplatin | 18 Years - 130 Years | AstraZeneca | |
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | NCT03944772 | Non-Small Cell ... | Osimertinib Savolitinib Gefitinib Necitumumab Durvalumab Carboplatin Pemetrexed Alectinib Selpercatinib Selumetinib Etoposide Cisplatin Datopotamab der... | 18 Years - 130 Years | AstraZeneca | |
| Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer | NCT03592641 | Colorectal Carc... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Rectal... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... Stage IVC Colon... Stage IVC Recta... Unresectable Co... Unresectable Re... | Savolitinib | 18 Years - | National Cancer Institute (NCI) | |
| A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer | NCT02897479 | Lung Sarcomatoi... | Savolitinib | 18 Years - | Hutchmed |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
